EyePoint, Inc. · NASDAQ:EYPT
EyePoint — EyePoint Pharmaceuticals — Investor Presentation (February 2025)
31 slides from EyePoint's investor presentation, February 2025
Slide 1: Investor Presentation
Investor Presentation February 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
Slide 2: Legal Disclaimers
Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, even
Slide 3: EyePoint: The Leader in Sustained Release Drug Delivery for Retinal Disease
EyePoint: The Leader in Sustained Release Drug Delivery for Retinal Disease 1 DURAVYU™: patent protected vorolanib featuring new MOA delivered via best-in-class IVT delivery technology, Durasert E™ 2 Most robust dataset in wet AMD and DME among all sustained delivery programs in development 3 Two on
Slide 4: Pipeline Leveraging Durasert E Drug Delivery Technology
Pipeline Leveraging Durasert E™ Drug Delivery Technology Anticipated Next Durasert E™ Programs Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Milestone Wet AMD Enrollment completion in PIVOTAL TRIALS UNDERWAY 2H 2025 DURAVYU™ – (vorolanib intravitreal insert) (f/k/a EYP-1901) FDA mtg expected
Slide 5: Durasert E Sustained-Release Drug Delivery Technology
Sustained-Release Drug Delivery TECHNOLOGY • Standard in-office IVT injection DURASERT E™ • Continuous dosing • Zero-order kinetics drug release Bioerodible Durasert E™: • Solid injectable insert • Drug formulated within a bioerodible matrix • Designed to release drug load before matrix fully erodes
Slide 6: Vorolanib is a Best-In-Class TKI that Selectively Inhibits all Forms of the VEGF Receptor
Vorolanib is a Best-In-Class TKI that Selectively Inhibits all Forms of the VEGF Receptor Pathological angiogenesis and vascular instability underlie wet AMD ANG2 PLGF VEGFB VEGFA VEGFC VEGFD ANG1 PDGF • Potent and highly selective pan-VEGF receptor inhibitor • Composition of matter patent into 2037
Slide 7: DURAVYU: Vorolanib in Bioerodible Durasert E
DURAVYU: Vorolanib in Bioerodible Durasert E™ DURAVYU™ Bioerodible Insert • Immediately bioavailable – reaches therapeutic levels within hours • Constant dosing – zero-order kinetics release for at least six months • Controlled drug release – bioerodible matrix controls drug release; no free-floatin
Slide 8: DURAVYU Demonstrated Positive Efficacy and Favorable Safety Profile Across Multiple Clinical Trials
DURAVYU Demonstrated Positive Efficacy and Favorable Safety Profile Across Multiple Clinical Trials and Indications DURAVYU HAS BEEN EVALUATED IN OVER 190 PATIENTS TO DATE ACROSS MULTIPLE INDICATIONS Clinical Indication Safety Key Efficacy Outcomes Trial • Stable BCVA and CST DAVIO wet AMD • 74% red
Slide 9: Phase 2 VERONA Clinical Trial in DME – Six-Month Results
Phase 2 VERONA Clinical Trial in DME – Six-Month Results IMMEDIATE BIOAVAILABILITY AND SUSTAINED DELIVERY FOR AT LEAST SIX MONTHS DME, diabetic macular edema ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Data as of January 16, 2025. Preliminary data pending final analysis.
Slide 10: Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need
Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments up to 5-6 54.9M 25% $3.9B 51% letters Patients in the US with Develop DME within Global market Delayed/missed Vision loss from diabetes by 20301 10 years2 by 20303 treatment visits4 missed inject
Slide 11: Phase 2 VERONA Clinical Trial is a Randomized, Open-Label, Aflibercept Controlled Trial
Phase 2 VERONA Clinical Trial is a Randomized, Open-Label, Aflibercept Controlled Trial as a Potential Treatment for DME PRIMARY ENDPOINT -D28 to D1 W4 W8 W12 W16 W20 W24 • Objectives: -D7 • Evaluate the safety and DURAVYU efficacy of DURAVYU in 1.3mg patients with active DME (CST (n=10) >325μm) DUR
Slide 12: VERONA Clinical Trial Supplement Criteria
VERONA Clinical Trial Supplement Criteria Starting at Week 4: • Reduction in BCVA ≥10 letters due to DME1 • Reduction in BCVA of 5-9 letters and >75 microns of new fluid at two consecutive visits1 • Increase of ≥100 microns of new fluid vs. Baseline (Day 1)2 • Investigator discretion Starting at Wee
Slide 13: VERONA: Phase 2 Clinical Trial Met Primary and Secondary Endpoints
DURAVYU 2.7mg - 24 WEEK EFFICACY RESULTS: • Primary endpoint achieved - extended time to first VERONA: supplemental injection vs. aflibercept control • Early and sustained BCVA improvement = +7.1 letters Phase 2 Clinical • Early and sustained CST improvement = -76 microns Trial Met Primary • 73% sup
Slide 14: VERONA: Single DURAVYU 2.7mg Treatment Demonstrated Clinically Meaningful Improvement in BCVA
VERONA: Single DURAVYU 2.7mg Treatment Demonstrated Clinically Meaningful Improvement in BCVA; Supports Noninferiority in Pivotal Trial MEAN CHANGE IN BCVA FROM BASELINE Mean Change in BCVA vs Aflibercept DURAVYU 2.7mg -0.2 Early and sustained VA improvement +7.3 +7.1 +6.9 BCVA, best-corrected visua
Slide 15: VERONA: DURAVYU 2.7mg Demonstrated Improved and Controlled Anatomy with 74% More Drying
VERONA: DURAVYU 2.7mg Demonstrated Improved and Controlled Anatomy with 74% More Drying than Aflibercept Control MEAN CHANGE IN CST FROM BASELINE Mean Change in CST vs Aflibercept DURAVYU 2.7mg -32.2 um -43.7 um -71.1 um -75.9 um CST: central subfield thickness Data as of January 16, 2025. Prelimina
Slide 16: VERONA: Greater Proportion of Supplement-Free Eyes vs. Aflibercept
VERONA: Eyes Treated with DURAVYU had a Greater Proportion of Supplement-Free Eyes vs. Aflibercept Control up to Six Months SUMMARY OF CUMULATIVE SUPPLEMENT-FREE RATES 100% 100% 100% 100% 2.7mg DURAVYU reduced treatment burden by over two-thirds 16 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Res
Slide 17: VERONA Case Study 1 - 2.7mg Dose Patient
Phase 2 VERONA Clinical Trial Case Study 1 - 2.7mg Dose Pt - Immediate Drying with Improved Vision After Single DURAVYU Treatment and No Supplementation - Prior treatment = 2x Eylea, 1x Vabysmo in past 12 months Day 1 Week 4 BCVA: 46 BCVA: 65 Week 16 Week 24 BCVA: 67 BCVA: 66 17 ©2025 EyePoint Pharm
Slide 18: VERONA Case Study 2 - 2.7mg Dose Patient
Phase 2 VERONA Clinical Trial Case Study 2 - 2.7mg Dose Patient- Continued Drying at Week 24 with Improved VA After Single DURAVYU Treatment and No Supplementation - Prior treatment = 1x Avastin, 5x Vabysmo in past 7 months Day 1 Week 4 BCVA: 73 BCVA: 74 Week 16 Week 24 BCVA: 80 BCVA: 80 18 ©2025 Ey
Slide 19: Continued Favorable Safety and Tolerability Profile in VERONA Clinical Trial
Continued Favorable Safety and Tolerability Profile in VERONA Clinical Trial • No reported DURAVYU-related ocular SAEs or systemic SAEs • No cases of: • Endophthalmitis • Retinal vasculitis (occlusive or non-occlusive) • Insert migration • Intraocular inflammation (IOI) • No discontinuations >190 pa
Slide 20: VERONA: Phase 2 Clinical Trial Highlights
VERONA: Phase 2 Clinical Trial Highlights ✔ Primary endpoint met for both DURAVYU doses ✔ Demonstrated immediate clinical bioavailability ✔ Achieved clinically meaningful results without a full load of aflibercept ✔ Significant improvement in vision paired with a meaningful reduction in treatment bu
Slide 21: Positive Phase 2 VERONA Data Supports Advancement to Phase 3 Pivotal Program
Positive Phase 2 VERONA Data Supports Advancement to Phase 3 Pivotal Program – Expected Initiation by End of 2025 Next Steps: • Continue development of Phase 3 clinical protocol – non-inferiority design • Discuss Phase 2 results and proposed Phase 3 clinical protocol with regulatory agencies (FDA, E
Slide 22: DURAVYU LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD
DURAVYU LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD NON-INFERIORITY VERSUS AN AFLIBERCEPT CONTROL ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
Slide 23: Phase 3 Trials are Designed to Enable Global Regulatory Approvals for DURAVYU
Phase 3 Trials are Designed to Enable Global Regulatory Approvals for DURAVYU LUGANO AND LUCIA TRIALS: GLOBAL, RANDOMIZED, DOUBLE-MASKED, AFLIBERCEPT CONTROLLED OBJECTIVE TRIAL DESIGN • ~400 patients per trial Demonstrate DURAVYU, when • Two arms administered every six months, • 2.7mg DURAVYU achiev
Slide 24: DURAVYU in Wet AMD Phase 3 Pivotal Trial Design
DURAVYU™ in Wet AMD Phase 3 Pivotal Trial Design W60- W84-W W96 Screening D1 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W80 W76 92 EOS d ose RANDOMIZATION DURAVYU DURAVYU DURAVYU DURAVYU DURAVYU™ n t D 2.7mg t P atie A F irs 2 0 26 / L UCI Data in G A NO line Aflibercept LU Top 2mg q8W AF
Slide 25: Exceptional Enrollment to Date Driven by Significant Investigator and Patient Enthusiasm
Exceptional Enrollment to Date Driven by Significant Investigator and Patient Enthusiasm June October December January 2H 2026 2024 2024 2025 2025 Topline data 2024 for pivotal Final Phase 3 First patient in First patient in LUGANO trial Expected full program protocols LUGANO trial LUCIA trial ~1/3
Slide 26: Commercial Manufacturing Facility Opened in October 2024
Commercial Manufacturing Facility Opened in October 2024 ✔ New manufacturing site for commercial production of DURAVYU ✔ Located in Northbridge, MA ✔ Built to EYPT specifications by landlord preserving upfront cash investment ✔ Built to US FDA and EU EMA standards ✔ 40,000sf cGMP manufacturing facil
Slide 27: EYP-2301: razuprotafib in Durasert E
EYP-2301: razuprotafib in Durasert E™ A SUSTAINED DELIVERY TIE-2 AGONIST FOR SEVERE RETINAL DISEASES ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
Slide 28: EYP-2301: Razuprotafib in Durasert E is a Patented TIE-2 Agonist
EYP-2301: Razuprotafib in Durasert E™ is a Patented TIE-2 Agonist as a Potential New MOA for Treating Serious Retinal Diseases EYP-2301 targets vascular endothelial protein tyrosine phosphatase (VE-PTP) activating TIE-2 and downregulating ANG2 to maintain vascular stability in the retina • Tie-2 act
Slide 29: On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones
On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones DURAVYU™ ✓ Positive EOP2 meeting with FDA for wet AMD April 2024 ✓ PAVIA for NPDR topline data May 2024 ✓ DAVIO 2 12-month data Jue 2024 ✓ Positive interim VERONA data October 2024 ✓ First patient dosed – LUG
Slide 30: EyePoint: The Leader in Sustained Release Drug Delivery for Retinal Disease
EyePoint: The Leader in Sustained Release Drug Delivery for Retinal Disease 1 DURAVYU™: patent protected vorolanib featuring new MOA delivered via best-in-class IVT delivery technology, Durasert E™ 2 Most robust dataset in wet AMD and DME among all sustained delivery programs in development 3 Two on
Slide 31: Investor Presentation
Investor Presentation February 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint Pharmaceuticals — Investor Presentation (February 2025) on 6ix